Oasmia Pharmaceutical AB News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

01.03.19	Oasmia Pharmaceutical AB (publ) (GlobeNewswire)
05.02.19	NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL) - UPDATED VERSION (GlobeNewswire)
05.02.19	NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL) (GlobeNewswire)
31.01.19	Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ) (GlobeNewswire)
22.01.19	Oasmia Pharmaceutical AB’s (publ, ”Oasmia”) decision to cancel the extraordinary general meeting on January 25, 2019 (GlobeNewswire)
21.01.19	Oasmia announces that the extraordinary general meeting 25 January 2019 is cancelled (GlobeNewswire)
15.01.19	European Medicines Agency validates Oasmia Pharmaceutical AB’s application to add efficacy data to the approved Apealea® product information (GlobeNewswire)
17.12.18	Clarification from the Board of Directors and Management of Oasmia Pharmaceutical AB (publ), “Oasmia” due to Per Arwidsson’s and Arwidsro Investment AB’s request for convening an Extraordinary General (GlobeNewswire)
14.12.18	NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL) (GlobeNewswire)
30.11.18	Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ) (GlobeNewswire)
30.11.18	Oasmia Pharmaceutical AB (publ) Interim report for the period May – October 2018 (GlobeNewswire)
29.11.18	Oasmia Pharmaceutical AB announces new agreement with Baxter Oncology GmbH for global commercial manufacturing of Apealea® (GlobeNewswire)
28.11.18	Oasmia intends to issue notice to an extraordinary general meeting at the request of a shareholder and announces that it is subject to legal proceedings with a major shareholder concerning the company (GlobeNewswire)
22.11.18	Oasmia Pharmaceutical Receives Approval from European Commission for Apealea® (paclitaxel micellar) in the European Union (GlobeNewswire)
20.11.18	New U.S. patent related to Oasmia Pharmaceutical’s nanotechnology platform XR17 has been granted (GlobeNewswire)
01.11.18	Oasmia completes a private placement of new convertible instruments in the amount SEK 80 million (GlobeNewswire)
31.10.18	Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ) (GlobeNewswire)
03.10.18	Oasmia Presents Positive Efficacy and Safety Data for Doxophos Vet in Treatment of Naïve Dogs with Lymphoma (GlobeNewswire)
30.09.18	Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ) (GlobeNewswire)
25.09.18	Annual General Meeting of Oasmia Pharmaceutical AB (publ) held on 25 September 2018 (GlobeNewswire)
21.09.18	Oasmia Pharmaceutical Receives Positive CHMP Opinion for Apealea® (paclitaxel micellar) in the European Union (GlobeNewswire)
18.09.18	Update regarding the Market Authorization Application of Apealea in the European Union (GlobeNewswire)
07.09.18	Oasmia completes a private placement of new convertible instruments in the amount SEK 35.2 million (GlobeNewswire)
31.08.18	Oasmia Pharmaceutical AB (publ) Interim report for the period May – July 2018 (GlobeNewswire)
30.08.18	Notification from Oasmia Pharmaceutical AB (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Oasmia Pharmaceutical AB

Aktien Top/Flop

Meistgelesene Nachrichten